Penn Center for Innovation

Dimension Therapeutics

Posted on May 6, 2016 — Kat Hinkel

PCI facilitated a new research collaboration between Dimension Therapeutics and Penn Medicine to advance certain gene therapies for inherited metabolic diseases.  Dimension’s collaboration will focus on research conducted with Dr. James Wilsonand  will include programs designed to treat citrullinemia type 1, phenylketonuria (PKU), and Wilson disease, a rare genetic disease associated with the liver that causes severe copper poisoning of the liver, brain, and other vital organs.
Press Release
GEN News – Dimension Therapeutics, Penn Med Launch Gene Therapy Collaboration

Category: